Market Overview - The A-share pharmaceutical and biotechnology index rose by 7.81%, outperforming the CSI 300 index by 5.03 percentage points and the ChiNext index by 2.10 percentage points, ranking 6th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index increased by 10.26%, surpassing the Hang Seng China Enterprises Index by 11.57 percentage points [4] R&D Progress - Yiming Anke's IMM2510 and Tida Pexip's clinical application have made new progress in undertaking [5] - Drug Jie's Tiengoteini is currently in Phase III clinical trials; Shiyao Group's SYS6017 is in Phase II clinical trials; and Shiyao Group's SYH2085 is in Phase I clinical trials [5] Sector Insights - The brain-computer interface sector has shown active performance, entering an industrialization critical point, with major countries like China and the U.S. launching support plans [6] - China's 14th Five-Year Plan identifies brain-computer interfaces as one of the six future industries, with goals set for technological breakthroughs by 2027 and the formation of an industrial ecosystem by 2030 [6] - The global brain market is projected to reach $7.63 billion by 2029, indicating a rapidly opening blue ocean market [6] - Three categories of investment targets are recommended: 1) Medical scene integrators benefiting from insurance payment integration and existing rehabilitation needs 2) Leaders in invasive/semi-invasive technologies with significant technical advantages and long-term potential 3) Comprehensive support providers focusing on high-certainty areas like supply chain production and clinical development [6] Investment Strategy - Future investments in the pharmaceutical sector should increasingly focus on the clinical value of medicines, addressing clinical needs of patients and doctors [7] - Both domestic medical insurance policies and global expansion strategies are placing higher premiums on clinical value [7] - The strategy emphasizes the innovative drug industry chain and innovative medical devices [7]

Core Insights - The patent for the core compound of semaglutide, known as a weight loss miracle drug, is set to expire in China on March 20, 2026, which has led to recent price reductions for the drug [1] - Novo Nordisk has announced price cuts for semaglutide to alleviate the financial burden of obesity treatment and to allow more patients to benefit from the medication [1] - The expiration of the patent is expected to intensify competition in the market as other companies prepare to launch biosimilars [2] Pricing and Market Dynamics - The price of semaglutide injection (2.27mg/mL×3mL) has decreased from 1893.67 yuan to 987.48 yuan, and the 3.2mg/mL version has dropped from 2463 yuan to 1284.36 yuan [1] - E-commerce platforms have become significant channels for consumers to purchase semaglutide, although there are concerns about the adequacy of prescription verification processes [2] Regulatory and Safety Considerations - Semaglutide is classified as a prescription drug, requiring strict approval processes and clinical trials before market release [3] - Novo Nordisk emphasizes the importance of using semaglutide under the guidance of qualified healthcare professionals to ensure safety and efficacy [3] - The effectiveness and safety of semaglutide have been validated in 58 global clinical studies, with approximately 38 million patient-years of usage experience reported [3]

Core Viewpoint - The announcement indicates that the application for the上市 of the combination drug Ploglitazone Metformin extended-release tablets has been accepted by the National Medical Products Administration of China, representing a significant step in the company's innovative drug development [1] Group 1: Product Development - The product is a Class 1 innovative drug combining Ploglitazone and Metformin in an extended-release formulation, aimed at treating adult patients with Type 2 Diabetes Mellitus (T2DM) [1] - The intended indication is for patients with inadequate blood sugar control on Metformin monotherapy or those currently receiving a combination of Ploglitazone and Metformin [1] Group 2: Clinical Trial Results - Phase III clinical trials have demonstrated that Ploglitazone shows good efficacy and safety in initial treatment of T2DM patients and those with inadequate control on Metformin monotherapy [2] - The combination of Ploglitazone and Metformin has shown significant and sustained blood sugar-lowering effects with a lower incidence of hypoglycemia compared to Metformin alone [2] - The product has a low potential for drug interactions and does not require dosage adjustment for patients with mild to moderate renal impairment [2] Group 3: Market Strategy - The combination formulation simplifies treatment regimens and significantly improves patient adherence, leading to more effective blood sugar control [2] - The company is actively advancing the clinical development of a three-drug combination formulation consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [2]

Core Viewpoint - The application for the上市 of Shijiazhuang Pharmaceutical Group's innovative drug, Ploglitazone Metformin Sustained-Release Tablets, has been accepted by the National Medical Products Administration of the People's Republic of China, indicating a significant step in the company's product development pipeline [1] Group 1 - The product is a combination of the innovative drug Ploglitazone and Metformin, classified as a type 2.3 chemical drug registration, aimed at treating adult patients with type 2 diabetes mellitus (T2DM) [1] - Ploglitazone is a DPP-4 inhibitor that increases endogenous active GLP-1 levels, enhancing insulin secretion and suppressing glucagon secretion to improve hyperglycemia [1] - Metformin reduces hepatic glucose production and intestinal glucose absorption while increasing peripheral tissue sensitivity to insulin [1] Group 2 - Phase III clinical trials have confirmed that Ploglitazone demonstrates good efficacy and safety in T2DM patients, showing significant and sustained blood sugar reduction compared to Metformin monotherapy, with a lower incidence of hypoglycemia [2] - The combination of Ploglitazone and Metformin has a lower likelihood of drug interactions and does not require dosage adjustment for patients with mild to moderate renal impairment [2] - The combination formulation simplifies treatment regimens and significantly improves patient adherence, leading to more effective blood sugar control [2] - The company is actively advancing the clinical development of a three-drug combination formulation consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [2]

Core Viewpoint - The application for the上市 of the combination drug Ploglitazone Metformin extended-release tablets developed by the company has been accepted by the National Medical Products Administration of China [1] Group 1: Product Information - The product is a first-class innovative drug combining Ploglitazone and Metformin in a sustained-release formulation, aimed at treating adult patients with type 2 diabetes mellitus (T2DM) [1] - The proposed indication is for use in T2DM patients who have inadequate blood sugar control with Metformin monotherapy or are currently receiving a combination of Ploglitazone and Metformin [1] Group 2: Clinical Trial Results - Phase III clinical trials have confirmed that Ploglitazone demonstrates good efficacy and safety in initial treatment of T2DM patients and those with inadequate blood sugar control on Metformin monotherapy [2] - Compared to Metformin monotherapy, the combination of Ploglitazone and Metformin shows significant and sustained blood sugar-lowering effects with a lower incidence of hypoglycemia [2] - The product has a low potential for drug interactions and does not require dosage adjustment for patients with mild to moderate renal impairment [2] Group 3: Treatment Simplification - The combination formulation simplifies treatment regimens and significantly improves patient adherence, leading to more effective blood sugar control compared to the use of two separate formulations [2] - The company is actively advancing the clinical development of a three-drug combination formulation consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [2]

在初始治療的T2DM患者以及二甲雙胍單藥治療血糖控制不佳的T2DM患者中開展的Ⅲ期臨 床試驗證實，普盧格列汀具有良好的有效性和安全性。與二甲雙胍單藥治療相比，普盧格 列 汀 聯 合 二 甲 雙 胍 具 有 顯 著 且 持 久 的 降 糖 作 用 ， 低 血 糖 發 生 率 較 低 ， 且 安 全 性 良 好 。 此 外，該產品與其他藥物發生相互作用的可能性較低，輕中度腎功能不全患者服用該產品時 無需調整劑量。與兩種單方製劑聯合應用相比，複方製劑可簡化治療方案、顯著提高患者 依從性，從而更有效地控制血糖。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 普盧格列汀二甲雙胍緩釋片的上市申請 獲國家藥監局受理 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 ...

Core Insights - The Huabao CSI Hong Kong Stock Connect Medical Theme ETF (159137) closed with a gain of 0.38% on January 12, with a trading volume of 173 million yuan [1] Fund Overview - The fund was established on December 31, 2025, and is officially named Huabao CSI Hong Kong Stock Connect Medical Theme Exchange-Traded Fund [1] - The management fee is set at 0.50% per annum, while the custody fee is 0.10% per annum [1] - The performance benchmark for the fund is the return of the CSI Hong Kong Stock Connect Medical Theme Index, adjusted for the RMB exchange rate [1] Fund Management - The current fund manager is Zhang Fang, who has managed the fund since its inception, achieving a return of 4.33% during the management period [1] Top Holdings - The latest report indicates that the top holdings of the ETF include: - WuXi Biologics: 2.65% holding, valued at approximately 7.49 million yuan [2] - JD Health: 2.02% holding, valued at approximately 5.71 million yuan [2] - WuXi AppTec: 1.44% holding, valued at approximately 4.07 million yuan [2] - Crystal Digital Holdings: 0.98% holding, valued at approximately 2.76 million yuan [2] - Alibaba Health: 0.93% holding, valued at approximately 2.63 million yuan [2] - WuXi AppTec Holdings: 0.86% holding, valued at approximately 2.43 million yuan [2] - Sinopharm: 0.72% holding, valued at approximately 2.04 million yuan [2] - Genscript Biotech: 0.55% holding, valued at approximately 1.55 million yuan [2] - Ping An Good Doctor: 0.46% holding, valued at approximately 1.31 million yuan [2] - CSPC Pharmaceutical Group: 0.41% holding, valued at approximately 1.17 million yuan [2]

Group 1 - The A-share and Hong Kong stock markets showed strength on January 12, with the innovative drug concept experiencing fluctuations after several days of rebound; the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index fell by 0.63% at the time of reporting, while stocks like CSPC Pharmaceutical Group, BeiGene, and Boteng Co., Ltd. saw slight increases [1] - Since the beginning of 2026, as of the close on January 9, the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index has rebounded over 10% cumulatively [1] - The Tianhong Innovative Drug ETF (517380) was actively traded, with a transaction amount exceeding 40 million yuan and a premium rate of 0.78% at the time of reporting; it has seen continuous capital inflow, accumulating over 170 million yuan from January 7 to 9 [1] Group 2 - According to Zhongtai Securities, it is recommended to focus on three dimensions for investment in 2026: "innovative drugs and their industrial chain, demand recovery and operational turning points, and AI+" [2] - Continuous attention should be paid to the AI+ theme, the positive catalysts from the JPM conference in the innovative drug sector, and the potential for exceeding annual performance forecasts or clearing turning point opportunities [2]

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF by Huabao (159137) is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with a strong performance in both the Hong Kong and A-share medical sectors at the beginning of 2026 [1][2]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [2]. - The underlying index, the "CSI Hong Kong Stock Connect Medical Theme Index," has seen a 14.25% increase from January 1 to January 9, 2026, and a total annual increase of 48.20% in 2025, indicating a strong recovery in the Hong Kong medical sector [2][4]. - The ETF's launch coincides with a rare "sixteen consecutive days of gains" in the Shanghai Composite Index, reflecting heightened investor enthusiasm [1]. Group 2: Investment Strategy and Composition - The ETF covers four major sectors within the Hong Kong medical field: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][4]. - The top ten constituents of the index include major players such as WuXi Biologics (15.28% weight), JD Health (11.84%), and Alibaba Health (5.42%), collectively accounting for 63.89% of the index [4]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized by significant growth potential, driven by an aging population and increasing healthcare demands, with the CXO market expected to grow at a CAGR of 26.56% from 2020 to 2025 [4]. - The index's valuation remains relatively low, with a TTM P/E ratio of 29.43, which is below historical averages, suggesting a favorable entry point for investors [5].

Group 1 - Tencent Holdings (00700) had a net inflow of 1.953 billion, representing a 14.71% increase in net inflow [1][2] - Xiaomi Group-W (01810) saw a net inflow of 1.634 billion, with a net inflow ratio of 22.31% [1][2] - The top three stocks with the highest net outflow were China Mobile (00941) at -1.137 billion, SMIC (00981) at -1.079 billion, and Kuaishou-W (01024) at -286 million [1][2] Group 2 - The highest net inflow ratios were recorded by Sichuan Chengyu Expressway (00107) at 72.73%, Shanghai Industrial Holdings (00363) at 56.73%, and Qingdao Port (06198) at 50.96% [1][3] - The stocks with the largest net outflow ratios included China National Building Material (03323) at -61.83%, Stone Pharmaceutical Group (02005) at -61.03%, and CITIC International Telecommunications (01883) at -54.38% [1][3]